What’s Next?







It’ll be fun to watch all the leftover Pacira reps “pivot” into nerve block with the pending lawsuit against the ASA while everyone infiltrating Exparel upgrades to Zynrelef. Limited label won’t be a major problem, 60% of Exparel’s business is in Ortho and nobody likes making 120 sticks in a TKA. Hospitals were already looking for a reason to kick Exparel out before their price increases,